Labetalol versus Methyldopa for Treatment of Pregnancy Induced Hypertension

Maria  Arshad; Sahar Farooq; Kaukab Majeed; Usman Khalid; Afeera Afsheen; Pareesae Artemis

doi:10.51253/pafmj.v74i4.9338

Authors

Maria Arshad Department of Gynecology, Combined Military Hospital, Bannu/National University of Medical Sciences (NUMS) Pakistan
Sahar Farooq Department of Gynecology, Pakistan Ordnance Factories Wah Hospital, Rawalpindi Pakistan
Kaukab Majeed Department of Anesthesia, Pak Emirates Military Hospital/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Usman Khalid Department of Gynecology, Combined Military Hospital, Bannu/National University of Medical Sciences (NUMS) Pakistan
Afeera Afsheen Department of Gynecology, Combined Military Hospital, Multan/National University of Medical Sciences (NUMS) Pakistan
Pareesae Artemis Department of Gynecology, Combined Military Hospital, Multan/National University of Medical Sciences (NUMS) Pakistan

DOI:

https://doi.org/10.51253/pafmj.v74i4.9338

Keywords:

Labetalol, Methyldopa, Pregnancy induced hypertension.

Abstract

Objective: To compare the mean fall in blood pressure with oral Labetalol versus Methyldopa in treating pregnancy induced hypertension.

Study Design: Quasi-experimental study.

Place and Duration of Study: Department of Gynecology, Combined Military Hospital, Bannu Pakistan, from Aug 2020-Feb 2021.

Methodology: After approval from institutional ethical committee and informed consent, sixty females with Pregnancy Induced Hypertension were included who were segregated into two groups. Group-A who took oral Labetalol 100 mg three or four times a day (up to 1200 mg per day) until the targeted blood pressure (<120/80 mmHg) was achieved. While Group-B took oral Methyldopa 250mg per day 3 to 4 up to 500 mg until targeted blood pressure(<120/80)was achieved. All patients were followed-up after one week of therapy. Primary outcome was mean fall in systolic and diastolic blood pressure after 5 days of treatment.

Results: The mean systolic and diastolic blood pressures were analogous in both Groups A and B, i.e. 152.33±6.53/100.33±4.54 mmHg versus 151.17±5.83/99.50±4.01 mmHg respectively. The mean fall in systolic BP in Group-A was 15.50±4.80 mmHg and in Group-B was 7.33±2.86 mmHg (p-value<0.0001) and mean fall in diastolic BP in Group-A was 13.17±5.80 mmHg compared to 5.50 ± 4.22 mmHg in Group-B (p-value<0.001).

Conclusion: We concluded that Labetalol is more effective in reducing blood pressure as compared to Methyldopa in Pregnancy Induced Hypertension.

Downloads

Download data is not yet available.

References

Alalfy M, Eltaieb E, Soliman M, Labetalol in Comparison to Methyl Dopa in Treatment of Gestational Hypertension, A Randomized Trial. J Gynecol Res 2008; 4(1): 101.

Lomte D. An Open Label, Prospective, Single Center Study to Evaluate the Efficacy of Methyldopa & Labetalol in Treatment of Patients with Pregnancy-induced hypertension. World J Pharm Pharmaceut Sci 2015; 4(9): 1235-1241.

Roychoudhury B, Sanyal P, Chowdhury B, Oswal K. Comparative study of efficacy of Methyldopa vs Labetalol in the management of pregnancy induced hypertension in respect to maternal and perinatal outcomes. Glob J Med pub health 2015; 4(4): 1-5.

Padmaja D, Varalakshmi B. Labetalol vs Methyldopa in the treatment of mild to moderate pregnancy induced hypertension. . Indian J Appl Res 2017; 12.

Pentareddy MR, Shailendra D, Prasuna G, Subbaratnam Y, Naresh D, Katta R, et al . Safety and efficacy of Methyldopa and Labetalol in controlling blood pressure in hypertensive disorders of pregnancy. Int J Basic Clinic Pharmacol 2017; 6(4): 942-947.

http://doi.org/10.18203/2319-2003.ijbcp20171109

Sharif N, Usman I, Azhar T. Pregnancy induced hypertension: to compare efficacy of Methyldopa and Labetalol in management. Professional Med J 2016; 23(10): 1187-1193.

https://doi.org/10.17957/TPMJ/16.3489

Qasim A, Siddiqui MH, us Salam J, Nusrat U. Labetalol versus Methyldopa: efficacy in pregnancy induced hypertension. Gomal J Med Sci 2014; 12(4): 233-236.

Thakur V, Thakur A, Saroshe S. Comparison of effect of nifedipine, Labetalol and Methyldopa in treatment of hypertension in pregnancy in a tertiary care government hospital. Int J Reprod Contracept Obstet Gynecol 2016; 5(1): 1-7. http://doi.org/10.18203/2320-1770.ijrcog20151495

Srivastava B, Usha R, Bhardwaj R, Gaur S, Joshi G, Nag P. Comparative study of efficacy and adverse effect af Labetalol and Methyldopa in patients with pregnancy-induced hypertension. Indian J Pharamcol 2013; 45.

Dharwadkar KM, Dharwadkar SN, Rajagopal K, Gopakumar C. study of Methyldopa vs Labetalol in management of preeclampsia and gestational hypertension. Gynecol Obstet 2014; 4: 2161-2166.

Akhtar N, Hayat Z, Nazim F. Comparison between Labetalol adn Methyldopa in the treatment of pre-eclampsia. J Postgrad Med Inst 2018; 32(1): 35-39.

Arias F, Bhide AG, Arulkumaran S, Damania K, Daftary SN. Practical Guide to High Risk Pregnancy and Delivery-E-Book: Elsevier health sciences; 2008.

Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005; 330(7491): 565.

https://doi.org/10.1136/bmj.38380.674340.E0

Duley L, Meher S, Jones L. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev 2013(7). https://doi.org/10.1002/14651858.CD001449.pub3

Hernández-Díaz S, Van Marter LJ, Werler MM, Louik C, Mitchell AA. Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics 2007; 120(2): e272-e282.

https://doi.org/10.1542/peds.2006-3037

Steegers EA, Von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010; 376(9741): 631-644.

https://doi.org/10.1016/S0140-6736(10)60279-6

Abalos E, Duley L, Steyn DW, Gialdini C. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2018(10).

https://doi.org/10.1002/14651858.CD002252.pub4

Saftlas AF, Logsden-Sackett N, Wang W, Woolson R, Bracken MB. Work, leisure-time physical activity, and risk of preeclampsia and gestational hypertension. Am J Epidemiol 2004; 160(8): 758-765.

https://doi.org/10.1093/aje/kwh277

Skjærven R, Vatten LJ, Wilcox AJ, Rønning T, Irgens LM, Lie RT, et al. Recurrence of pre-eclampsia across generations: exploring fetal and maternal genetic components in a population based cohort. BMJ 2005; 331(7521): 877.

https://doi.org/10.1136/bmj.38555.462685.8F

Subhedar V, Inamdar S, Hariharan C, Subhedar S. Comparison of efficacy of Labetalol and Methyldopa in patients with pregnancy-induced hypertension. Int J Reprod Contracept Obstet Gynecol 2013; 2(1): 27-34.

https://doi.org/10.5455/2320-1770.ijrcog20130205

Lamming G, Symonds E. Use of Labetalol and Methyldopa in pregnancy‐induced hypertension. Br. J. Clin. Pharmacol 1979; 8(S2): 217S-222S.

https://doi.org/10.1111/j.1365-2125.1979.tb04784.x

El‐Qarmalawi A, Morsy A, Al‐Fadly A, Obeid A, Hashem M. Labetalol vs. Methyldopa in the treatment of pregnancy‐induced hypertension. Int J Gynecol Obstet 1995; 49(2): 125-130.

https://doi.org/10.1016/0020-7292(95)02351-C

Cruickshank D, Robertson A, Campbell D, MacGillivray I. Does Labetalol influence the development of proteinuria in pregnancy hypertension? A randomised controlled study. Eur J Obstet Gynecol Reprod Biol 1992; 45(1): 47-51.

https://doi.org/10.1016/0028-2243(92)90192-2

Lardoux H, Gerard J, Blazquez G, Chouty F, Flouvat B. Hypertension in pregnancy: evaluation of two beta blockers atenolol and Labetalol. Eur Heart J 1983; 4:35-40.

https://doi.org/10.1093/eurheartj/4.suppl_G.35

Michael C. Use of Labetalol in the treatment of severe hypertension during pregnancy. Br. J. Clin. Pharmacol1979; 8(S2): 211S-215S.

https://doi.org/10.1111/j.1365-2125.1979.tb04783.x